ERBB2 and prostate cancer: Biochemical studies have indicated that the mutant β4 integrin fails to promote cancer stem cell self-renewal due to a defective transactivation of ERBB2 and c-Met in prostate tumor progenitors: combined pharmacological inhibition of ERBB2 and c-Met greatly reduced the number of prostate cancer stem cells [603].